Lymphangioleiomyomatosis synonyms

Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease primarily affecting women, historically referred to by various names including pulmonary lymphangiomyomatosis. While the terminology has evolved, Lymphangioleiomyomatosis is the current, universally accepted medical term used in clinical practice, research, and international classification systems.

What are the historical and alternative names for Lymphangioleiomyomatosis?

In older medical literature, you may encounter different terms for Lymphangioleiomyomatosis, which can sometimes cause confusion for patients and their families. Historically, the condition was often described as pulmonary lymphangiomyomatosis. Other names that have appeared in clinical records or older case studies include lymphangioleiomyoma of the lung and, more rarely, benign metastasizing leiomyoma, though the latter is now recognized as a distinct clinical entity. These varying names reflect the evolving understanding of the disease's underlying pathology—specifically, the abnormal proliferation of smooth muscle-like cells (LAM cells) that obstruct airways and lymphatic vessels.

Why does Lymphangioleiomyomatosis have so many names?

The naming of Lymphangioleiomyomatosis has been influenced by the history of its discovery and the development of specialized imaging and molecular diagnostics. Because the disease involves the lungs, lymphatic system, and smooth muscle tissue, early researchers used descriptive terms based on the histological appearance of the tissue samples. As our understanding of the disease progressed—particularly the identification of mutations in the TSC1 or TSC2 genes—the medical community standardized the nomenclature to ensure consistent communication. Standardizing the name as Lymphangioleiomyomatosis helps clinicians worldwide coordinate care and allows patients to search for the most current, evidence-based research.

How is Lymphangioleiomyomatosis classified in medical systems?

Medical professionals and global health organizations use specific codes to categorize Lymphangioleiomyomatosis for diagnostic and billing purposes. These systems ensure that researchers and doctors are referring to the same condition. Key classification identifiers include:

• Orphanet: ORPHA:2384


• OMIM (Online Mendelian Inheritance in Man): #606690


• ICD-10: J84.89 (Other specified interstitial pulmonary diseases)


• ICD-11: CA20.0 (Lymphangioleiomyomatosis)

What is the current preferred term for the condition?

Today, Lymphangioleiomyomatosis is the only term used in professional clinical guidelines and scientific publications. Using this specific name is vital when searching for support through organizations like DiseaseMaps.org, where 9 community members have shared their experiences. By using the official term, patients can connect with others, find clinical trials, and access accurate information regarding the management of Lymphangioleiomyomatosis, which often involves specialized treatments like mTOR inhibitors.

Next steps

• Consult a Pulmonologist: Ensure your medical records use the term Lymphangioleiomyomatosis to avoid delays in specialized care.


• Verify Your Diagnosis: Discuss your genetic status (TSC-associated vs. sporadic) with a genetic counselor.


• Join the Community: Connect with others at DiseaseMaps.org to share experiences with this rare disease.


• Stay Informed: Regularly check NIH GARD for the most up-to-date clinical guidelines.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• Orphanet: Lymphangioleiomyomatosis (ORPHA:2384)


• NIH Genetic and Rare Diseases Information Center (GARD): Lymphangioleiomyomatosis


• OMIM: Lymphangioleiomyomatosis; LAM (Entry #606690)


• The LAM Foundation: Understanding the Basics of LAM